The US Food and Drug Administration has approved semaglutide 2.4 mg (Wegovy), a once-weekly subcutaneous injection, for the further denotation of treating obesity successful adolescents aged 12 years and older.
This is defined arsenic those with an archetypal BMI astatine oregon supra the 95th percentile for property and enactment (based connected CDC maturation charts). Semaglutide indispensable beryllium administered on with manner involution of a reduced calorie repast program and accrued carnal activity.
When Wegovy was approved for use successful adults with obesity successful June 2021, it was labeled a "game changer."
The caller support is based connected the results of the STEP TEENS signifier 3 proceedings of once-weekly 2.4 mg of semaglutide successful adolescents 12- to <18 years aged with obesity, the drug's manufacturer, Novo Nordisk, announced successful a press release.
In STEP TEENS, reported astatine Obesity Week 2022 successful November, and simultaneously published successful the New England Journal of Medicine, adolescents with obesity treated with semaglutide for 68 weeks had a 16.1% simplification successful BMI compared with a 0.6% summation successful BMI successful those receiving placebo. Both groups besides received manner intervention. Mean value nonaccomplishment was 15.3 kg (33.7 lb) among teens connected semaglutide, portion those connected placebo gained 2.4 kg (5.3 lb).
At the time, Claudia K. Fox, MD, MPH, co-director of the Center for Pediatric Obesity Medicine astatine the University of Minnesota Medical School — who was not progressive with the probe — told Medscape the results were "mind-blowing…we are getting adjacent to bariatric surgery results" successful these teen patients with obesity.
Semaglutide is simply a GLP-1 agonist, arsenic is simply a related agent, besides from Novo Nordisk, liraglutide (Saxenda), a regular subcutaneous injection, which was approved for use successful adolescents aged 12 and older successful December 2020. Wegovy is the archetypal play subcutaneous injection approved for usage successful adolescents.
Other agents approved for obesity successful those older than 12 successful the US see the operation phentermine and topiramate extended-release capsules (Qsymia) in June 2022, and orlistat (Alli). Phentermine is approved for those aged 16 and older.
For much diabetes and endocrinology news, travel america connected Twitter and connected Facebook .
English (US)